clevidipine has been researched along with bradykinin in 1 studies
| Studies (clevidipine) | Trials (clevidipine) | Recent Studies (post-2010) (clevidipine) | Studies (bradykinin) | Trials (bradykinin) | Recent Studies (post-2010) (bradykinin) |
|---|---|---|---|---|---|
| 127 | 19 | 62 | 14,195 | 355 | 1,520 |
| Protein | Taxonomy | clevidipine (IC50) | bradykinin (IC50) |
|---|---|---|---|
| B2 bradykinin receptor | Homo sapiens (human) | 0.0018 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gourine, AV; Pernow, J; Poputnikov, DM; Sjöquist, PO | 1 |
1 other study(ies) available for clevidipine and bradykinin
| Article | Year |
|---|---|
Calcium antagonist clevidipine reduces myocardial reperfusion injury by a mechanism related to bradykinin and nitric oxide.
Topics: Animals; Bradykinin; Bradykinin Receptor Antagonists; Calcium Channel Blockers; Drug Therapy, Combination; Female; Male; Myocardial Reperfusion Injury; Nitric Oxide; Nitric Oxide Donors; Pyridines; Receptor, Bradykinin B2; Receptors, Bradykinin; Swine | 2002 |